Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Nanobiotix ( (NBTX) ) just unveiled an announcement.
On September 30, 2025, Nanobiotix S.A. released its half-year financial report for the period from January 1 to June 30, 2025. The report highlights significant events and activities, including the development and commercialization of its product JNJ-1900 through a license agreement with Janssen. The company is focused on expanding the pipeline for JNJ-1900 and completing clinical trials, which are crucial for its future prospects and market positioning.
The most recent analyst rating on (NBTX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Nanobiotix stock, see the NBTX Stock Forecast page.
Spark’s Take on NBTX Stock
According to Spark, TipRanks’ AI Analyst, NBTX is a Neutral.
Nanobiotix’s stock score is primarily impacted by significant financial instability, marked by declining revenues and negative profitability. However, the stock’s strong technical momentum provides a counterbalance, suggesting potential short-term interest despite the company’s broader financial challenges. Valuation concerns persist due to the negative P/E ratio, reflecting non-profitability.
To see Spark’s full report on NBTX stock, click here.
More about Nanobiotix
Nanobiotix S.A. is a company operating in the biotechnology industry, focusing on the development of nanomedicine products. Its primary product, JNJ-1900 (formerly NBTXR3), is being developed for cancer treatment in collaboration with Janssen Pharmaceutica NV.
Average Trading Volume: 31,840
Technical Sentiment Signal: Buy
Current Market Cap: $791.8M
Find detailed analytics on NBTX stock on TipRanks’ Stock Analysis page.